The upgrade is nice and the downgrade sucks. The company probably did go conservative on the sales projection but I think the analysts are a bit lame.
I thought the update on 113 was the most significant part of the presentation. The fact that they have the dose up to 300mg without any significant safety issues and the drug appears to work well on brain mets was much more significant than the pona first year sales number, IMHO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.